Granulocyte–Macrophage Colony-stimulating Factor
Sensitive and Receptor-mediated Regulation by 1,25-Dihydroxyvitamin D₃ in Normal Human Peripheral Blood Lymphocytes

A. Tobler, J. Gasson, H. Reichel,* A. W. Norman,* and H. P. Koeffler
Department of Medicine, Division of Hematology/Oncology, University of California Los Angeles Medical Center, Los Angeles, California 90024; and *Department of Biochemistry, University of California, Riverside, California 92521

Abstract

We show that 1,25-dihydroxyvitamin D₃ (1,25(OH)₂D₃), the most hormonally active metabolite of vitamin D₃, modulates sensitively and specifically both the protein and messenger RNA accumulation of the multilineage growth factor granulocyte–macrophage colony-stimulating factor (GM-CSF). The regulation of GM-CSF expression is seen in both normal human mitogen-activated T lymphocytes and T lymphocytes from a line (S-LBL) transformed with human T cell lymphotropic virus 1 (HTLV-1). In contrast, cells from a HTLV-1 transformed T lymphocyte line (Ab-VDR) established from a patient with vitamin D-resistant rickets type II with undetectable 1,25(OH)₂D₃ cellular receptors are resistant to the action of 1,25(OH)₂D₃. Inhibition of GM-CSF expression by 1,25(OH)₂D₃ can occur independently of interleukin 2 regulation and is probably mediated through cellular 1,25(OH)₂D₃ receptors. We conclude that 1,25(OH)₂D₃ may be important in the physiology of hematopoiesis.

Introduction

Evidence is accumulating that the hormonally active metabolite of vitamin D₃, 1,25-dihydroxyvitamin D₃ (1,25(OH)₂D₃), might play an important role as an immunohematopoietic regulatory hormone (reviewed in references 1, 2). Specific 1,25(OH)₂D₃ receptors are present in normal human mitogen-activated and malignant T and B lymphocytes and myeloid cells (3, 4). 1,25(OH)₂D₃ enhances the in vitro differentiation of normal and leukemic myeloid stem cells towards macrophages (5-7). 1,25(OH)₂D₃ inhibits proliferation and suppresses interleukin 2 (IL-2) synthesis of mitogen-activated T lymphocytes (8-11). Human macrophages activated by γ-interferon synthesize 1,25(OH)₂D₃ (12, 13).

Survival, proliferation, and differentiation of hematopoietic cells are dependent on colony-stimulating factors (CSF). The granulocyte–macrophage colony-stimulating factor (GM-CSF), which is synthesized by activated T lymphocytes, has been cloned (14, 15). Recombinant and natural GM-CSF possess multilineage colony-stimulating activity (16, 17) and also enhances mature cell function of neutrophils and eosinophils (18, 19). We report here that 1,25(OH)₂D₃ sensitively and specifically inhibits the expression of GM-CSF in T lymphocytes.

Methods

Compounds. The vitamin D₃ metabolites (1,25(OH)₂D₃, 1,24,25(OH)₃D₃, and 25(OH)D₃) were a generous gift from Dr. M. Ussakovic, Hoffmann-La Roche, Inc., Nutley, NJ. The compounds were dissolved in 100% ethanol to a stock concentration of 1 × 10⁻³ M and stored at −20°C. The various concentrations (10⁻¹⁰-10⁻⁷ M) were obtained by diluting the stock solutions in phosphate-buffered saline (PBS). The concentration of ethanol did not exceed 0.1%. Recombinant human IL-2 was generously provided by Jürgen Besemer (Sanofi Ltd., Vienna, Austria). Phytoméhagglutinin (PHA) (Wellcome Diagnostics, Datford, England) was used in a final concentration of 0.5%.

Cells and liquid culture assay. The human cell lines S-LBL (20), Ab-VDR (H. P. Koeffler and A. W. Norman, unpublished observations), HL-60 (21), and KG-1 (22) were maintained in suspension culture T flask (Miles Laboratories Inc., Naperville, IL), containing alpha medium (Flow Laboratories Inc., Rockville, MD) and 10% fetal calf serum (FCS) (Irvine Scientific, Santa Ana, CA) in a humidified atmosphere of 7% CO₂. The medium was changed twice a week.

Human peripheral blood lymphocytes (PBL) and human bone marrow cells were obtained from normal volunteers and isolated from Ficoll-Hypaque density gradient (1.077 g/ml) (Sigma Chemical Co., St. Louis, MO). Monocytes were removed from PBL by their ability to adhere to plastic for 6 h. The PBL and the human HTLV-1 immortalized T lymphocyte cell lines (S-LBL, Ab-VDR) were cultured for 2 d at 1 × 10⁶ cells/ml in alpha medium—supplemented with 10% FCS in the presence of the various additives (vitamin D₃ compounds, PHA, IL-2) at 37°C in a humidified atmosphere of 7% CO₂. The conditioned media (CM) were stored at 4°C. Cell viability was not affected in the various experimental protocols, as determined by trypan blue exclusion.

Colony formation assay by two-layer agar techniques. The underlayer was plated in 1-ml portions in 35-mm petri dishes (Miles Laboratories Inc.) containing 0.5% agar, alpha medium, 16% FCS and CM from PBL as a source of CSF. CM obtained from the human T lymphocyte Mo cell line was used for control purpose at a final concentration of 1.5% (23). The overlayer contained the GM-CSF responder cells (bone marrow, KG-1), alpha medium, 16% FCS, penicillin, streptomycin, and 0.3% agar. The culture dishes were incubated at 37°C in a humidified atmosphere with 7% CO₂ for 10-13 d. Colonies (>40 cells) were counted using an inverted microscope.

Complementary DNA (cDNA) probes, Northern blot technique. The IL-2 cDNA was a generous gift from S. Clarke, Genetics Institute, Boston, MA (24). The IL-2 receptor cDNA was kindly provided by T. Nikaido (25). The IL-2 and the IL-2 receptor probes were [³²P]-labeled by the
random priming method as described (26). The GM-CSF probes were [32P]-labeled by nick translation (27).

For cytoplasmic RNA, freshly harvested cells were suspended in hypotonic buffer (10 mM Tris-HCl [pH 7.4], 1 mM KCl, 3 mM MgCl₂) and were lysed with Nonidet P-40 (0.3%). Nuclei were removed by centrifugation. Cytoplasmic RNA was extracted by the phenol/chloroform method as essentially described (28) and quantified by absorbance at 260 nm. Samples were denatured at 65°C for 10 min, size-separated by an agarose formaldehyde gel (1% agarose [Bethesda Research Laboratories, Gaithersburg, MD], 50 mM Na acetate, 10 mM Na₂ EDTA, 200 mM MOPS, and 2.2 M formaldehyde), and transferred to a nylon membrane filter (ICN Biomedicals Inc., Irvine, CA). Filters were dried, baked at 80°C in vacuo for 2 h, and then prehybridized for 16–24 h. Hybridizations with [32P]-labeled cDNA (1 × 10⁶ cpm/ml) were performed at 42°C for 16–24 h in a solution containing 50% (vol/vol) formamide, 2× SSC (1× SSC is 150 mM NaCl, 15 mM sodium citrate), 5× Denhardt's (1× Denhardt's is 0.02% Ficoll/0.02% polyvinylpyrrolidone/0.02% bovine serum albumin), 0.1% sodium dodecyl sulfate (SDS), 1 mM EDTA, 10% (vol/vol) dextran sulfate (500,000 mol wt) (Sigma Chemical Co.), and 100 μg/ml salmon sperm DNA (Sigma Chemical Co.). Filters were washed to a stringency of 0.1× SSC, 1% SDS at 65°C and exposed for 24–48 h at −70°C to XAR-5 film (Eastman Kodak Co., Rochester, NY).

Measurement of [14C]thymidine incorporation. S-LBl cells (1 × 10⁴/ml) were exposed in 24-well plates (Miles Laboratories Inc.) in quadruplicates for various durations (0, 6, 48 h) to 1,25(OH)₂D₃ (10⁻⁸ M). Cells were pulsed with 0.5 μCi of [14C]thymidine (New England Nuclear, Boston, MA) for 2 h at 37°C, washed twice in PBS, precipitated in 5% trichloroacetic acid (TCA) for 10 min, washed twice in 5% TCA, and heated at 80°C for 60 min. 200 μl of each sample was counted by liquid scintillation.

Measurement of [3H]thymidine incorporation. PBL (1 × 10⁴/ml) were cultured in the presence of 0.5% PHA and 1,25(OH)₂D₃ (10⁻⁷ M) in equal volumes (100 μl) in triplicates in 96-well plates (Corning Glass Works, Corning, NY). After 48 h, cells were pulsed with 1 μCi of [3H]thymidine (ICN Biomedicals Inc.) for 5 h at 37°C and harvested into glass fiber filter with a Mash II cell harvester (Skatron, Inc., Sterling, VA) and counted by liquid scintillation.

Results

Modulation of GM-CSF protein levels by 1,25(OH)₂D₃ and influence of IL-2 on GM-CSF expression in peripheral blood lymphocytes: dose response. The PBL (1 × 10⁴/ml) were cultured in the presence of increasing concentrations of 1,25(OH)₂D₃ (10⁻¹⁰–10⁻⁷ M) and PHA (0.5%). After 2 d, CFU activity of the CM was assayed for stimulation of clonal growth of both normal human granulocyte-macrophage colony-forming cells (GM-CFC) and the human myeloblastic leukemia cell line KG-1 (Fig. 1 A). Clonal growth of both GM-CFC and KG-1 cells is dependent on CSF (22). We found that 1,25(OH)₂D₃ decreased levels of GM-CSF protein in a dose-dependent fashion with a 50% reduction of CSF activity (ED₅₀) at ~5 × 10⁻¹⁰ M 1,25(OH)₂D₃ when tested on clonal growth of GM-CFC and KG-1 cells. Control dishes containing no 1,25(OH)₂D₃ formed 127±8 (±SD) GM-CFC and 62±10 (±SD) KG-1 colonies. No difference in colony formation could be observed when 1,25(OH)₂D₃ (10⁻⁴ M) was added directly to the culture dishes containing CM of PHA-activated PBL compared with the control dishes containing CM of PHA-stimulated PBL only.

Prior studies showed that 1,25(OH)₂D₃ decreased proliferation and IL-2 synthesis by PBL (8-11). We examined, therefore, whether IL-2 might affect the modulation of GM-CSF production by 1,25(OH)₂D₃ in lymphocytes (Fig. 1 A). The PBL were cultured for 48 h in the presence of a high concentration of recombinant human IL-2 (200 ng/ml/10⁶ cells), 1,25(OH)₂D₃ (10⁻¹¹–10⁻⁷ M) and PHA (0.5%); the CM was assayed for stimulation of GM-CFC. We found that the addition of IL-2 to the cultures slightly blunted but did not reverse the inhibitory action of 1,25(OH)₂D₃ on GM-CSF protein activity. The IL-2 alone

Figure 1. Modulation of GM-CSF expression by 1,25(OH)₂D₃ in PBL. Dose-response studies (A–C). (A) Regulation of GM-CSF protein production. PBL were cultured for 48 h in the presence of PHA and 1,25(OH)₂D₃. GM-CSF activity of the CM was tested by measuring clonal growth of both a normal human GM-CFC (a) and a leukemia myeloblastic cell line KG-1 (a). In a parallel series of experiments, recombinant IL-2 (200 ng/ml) was added to the cultures and the CM was assayed on GM-CFC (b). The IL-2 alone had no effect on clonal growth. (B and C) Regulation of GM-CSF mRNA levels (Northern blots). PBL were incubated for 48 hours with PHA and 1,25(OH)₂D₃. When probed with GM-CSF cDNA, a single band was detected at 0.9 kb consistent with the known length of GM-CSF mRNA (B). The same Northern blot was reprobed with IL-2 receptor cDNA, as a control (C). Two bands were observed at 1.4 and 3.5 kb consistent with IL-2 receptor mRNA. Time-response studies (D and E): (D) Regulation of GM-CSF protein production. PBL were exposed to PHA and for various durations (12-48 h) to 1,25(OH)₂D₃ (10⁻⁴ M). All time points were harvested after 48 h. GM-CSF activity was assayed on GM-CFC. (E) Regulation of GM-CSF mRNA levels (Northern blot). PHA-activated PBL were cultured for various durations (6-48 h) with 1,25(OH)₂D₃ (10⁻⁴ M). PBL at all time points were harvested after 48 h. Each experiment in A and D represents the mean±SD from three independent experiments with PBL from three different donors. RNA was extracted as described in Methods. Each lane in B, C, and E contains 30 μg cytoplasmic RNA. Results are expressed as a percent reduction of mRNA accumulation by 1,25(OH)₂D₃ as compared with the untreated control sample not exposed to 1,25(OH)₂D₃ (determined by densitometry on different exposures of prefixed autoradiograms).

Colonizing Factor Regulation by 1,25-Dihydroxyvitamin D₃

1701
had no effect on clonal growth of GM-CFC. CM from control cultures (PHA 0.5%, no IL-2, no 1,25(OH)2D3) stimulated a mean 243 ± 8 (±SD) GM-CFC per 2 × 106 mononuclear bone marrow cells.

**Modulation of GM-CSF mRNA levels by 1,25(OH)2D3 in PBL: dose response.** The modulation of GM-CSF mRNA levels of PBL cultured with various concentrations of 1,25(OH)2D3 was determined by Northern blot analysis (Fig. 1 B). The PBL were pooled from seven different donors, exposed for 2 d to increasing concentrations of 1,25(OH)2D3 (10−11–10−8 M) and PHA (0.5%) and the mRNA was extracted. A single band of hybridization was detected at 0.9 kb, which is consistent with GM-CSF mRNA (14, 15). The 1,25(OH)2D3 reduced mRNA accumulation in a dose-dependent manner with an ED50 of ~ 5 × 10−10 M as determined by densitometry reading. The same Northern blot was washed and reprobed with a human cDNA for the IL-2 receptor gene to exclude a nonspecific degradation of mRNA (Fig. 1 C). Two classes of IL-2 receptor mRNA could be observed at 1.4 and 3.5 kb, which is in accordance with previously reported data (25). No significant change of IL-2 receptor mRNA (1.4-kb band) could be detected.

**Modulation of GM-CSF protein and mRNA levels by 1,25(OH)2D3 in PBL: time response.** We examined whether 1,25(OH)2D3 might be able to down-regulate protein and mRNA levels of GM-CSF in PBL already activated by PHA (Fig. 1, D and E). For all time points, the PBL were exposed for 48 h to PHA (0.5%). The 1,25(OH)2D3 (10−8 M) was added to the cultures at times 0, 24, 36 h for the protein studies, and 0, 24, 42 h for the mRNA studies. Control samples were stimulated by PHA alone. We found that a 12-h exposure to 1,25(OH)2D3 inhibited GM-CSF protein production by ~ 50% in PBL previously activated with PHA for 36 h (Fig. 1 D), and a 6-h exposure to 1,25(OH)2D3 was sufficient to reduce mRNA levels of GM-CSF by ~ 50% in PBL previously activated for 42 h (Fig. 1 E).

**Regulation of GM-CSF mRNA levels by 1,25(OH)2D3 in a HTLV-1 immortalized T lymphocyte line (S-LB1).** We performed a parallel series of experiments using a human T lymphocyte line (S-LB1) established by infection of normal human T lymphocytes with HTLV-1 (20). These cells constitutively synthesize GM-CSF and express high levels of IL-2 receptors (29, 30). S-LB1 cells were exposed for 48 h to increasing concentrations of 1,25(OH)2D3 (10−11–10−7 M) (Figs. 2 A). The 1,25(OH)2D3 decreased GM-CSF mRNA levels in a dose-dependent fashion as shown on the Northern blot, and a 50% reduction of mRNA occurred at ~ 2.5 × 10−10 M. Time-response experiments showed that a 50% decrease of GM-CSF mRNA accumulation occurred within 6 h of exposure of S-LB1 cells to 1,25(OH)2D3 (10−8 M) (Fig. 2 B). For control purpose, the same samples were reprobed with IL-2 receptor cDNA (Fig. 2 C). Only a slight change of the IL-2 receptor mRNA levels (1.4-kb band) could be detected when S-LB1 cells were exposed to 1,25(OH)2D3 (10−8 M), as compared to the marked decrease of GM-CSF mRNA levels.

Receptor-mediated modulation of GM-CSF expression by vitamin D3 seco-steroids. We first studied the ability of other metabolites of vitamin D3 to regulate the accumulation of GM-CSF mRNA by S-LB1 cells (Fig. 3 A). The S-LB1 cells were cultured for 48 h with different vitamin D3 metabolites (10−8 M). The rank order of potency (1,25(OH)2D3 > 1,24,25(OH)2D3 > 25(OH)D3) of the metabolites to affect accumulation of GM-CSF mRNA paralleled the affinity of the metabolites to bind to the 1,25(OH)2D3 cellular receptors in other tissues (31). Secondly, we established a HTLV-1 immortalized T lymphocyte cell line derived from a patient with vitamin D-resistant rickets type II (Ab-VDR). Vitamin D-resistant rickets II is a heterogenous group of syndromes characterized by a decreased or absent ability of 1,25(OH)2D3 to bind to its cellular receptor (1, 32). Exposure of the Ab-VDR cells to 1,25(OH)2D3 (10−8 M, 10−10 M) for 48 h had little effect on GM-CSF mRNA accumulation (reduction of mRNA of ~ 15% compared with control samples, as determined by densitometry) (Fig. 3 B). These results are consistent with Ab-VDR cells having undetectable 1,25(OH)2D3 cellular receptors, as determined by sucrose density gradient and DNA chromatography analyses (H. P. Koeffler and A. W. Norman, unpublished observations).

**Influence of IL-2 on the expression of GM-CSF by S-LB1 cells.** Previous studies suggested that most HTLV-1-transformed T lymphocytes do not synthesize IL-2 (33). We probed S-LB1 mRNA with a human cDNA for IL-2 (Fig. 3 C). The PHA-stimulated PBL were used as a positive control and the human promyelocytic cell line HL-60 as a negative control. A single band could be detected at 0.9 kb in PHA-activated lymphocytes consistent with IL-2 mRNA (24). However, no IL-2 mRNA could be detected in S-LB1 cells and yet cells from the same passage were regulated very sensitively by 1,25(OH)2D3 (Fig. 2 A).
to 1,25(OH)₂D₃ had almost no effect on RNA synthesis. A 24-h exposure to 1,25(OH)₂D₃ decreased the incorporation of [³⁴C]uridine TCA precipitable counts by ~33% as compared with the control sample not treated with 1,25(OH)₂D₃.

**Table I. [³⁴C]Uridine Incorporation in S-LB1 Cells Exposed for Various Durations to 1,25(OH)₂D₃**

<table>
<thead>
<tr>
<th>Time exposed to 1,25(OH)₂D₃</th>
<th>Experiments</th>
<th>Mean percent inhibition, nos. 1 and 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>h (control)</td>
<td>cpm x 10⁴ (%)</td>
<td>cpm x 10⁴ (%)</td>
</tr>
<tr>
<td>0 (control)</td>
<td>9.8±0.17 (0)</td>
<td>1.26±0.03 (0)</td>
</tr>
<tr>
<td>6</td>
<td>9.6±0.04 (2)</td>
<td>1.17±0.03 (6)</td>
</tr>
<tr>
<td>24</td>
<td>6.4±0.04 (33)</td>
<td>0.85±0.03 (32)</td>
</tr>
</tbody>
</table>

[³⁴C]Uridine incorporation as a measurement of RNA metabolism. S-LB1 cells (1 x 10⁶/ml) were cultured in the presence of either ethanol control (≤ 0.01% ethanol) or 1,25(OH)₂D₃ (10⁻⁸ M). Results represent mean±SD of quadruplicate cultures of two independent experiments (Nos. 1 and 2). Numbers in parentheses denote percentage of inhibition as compared with control sample treated with no 1,25(OH)₂D₃. Analysis was performed as described in Methods.

**Proliferation studies ([³⁴H]thymidine incorporation).** We measured the effect of 1,25(OH)₂D₃ (10⁻⁷ M) on PHA-activated PBL by measuring [³⁴H]thymidine incorporation. After 48 h in culture, PHA-activated PBL incorporated 11,911±4,446 cpm/10⁶ cells. Treatment with 1,25(OH)₂D₃ (10⁻⁷ M) for 48 h resulted in a statistically insignificant (P > 0.5) decrease of [³⁴H]thymidine incorporation into PBL (8,728±2,097 cpm/10⁶ cells), representing a 17.6% inhibition as compared with the control samples not treated with 1,25(OH)₂D₃. The results represent the mean±SD for nine incubations.

**Discussion**

We report in the present in vitro study that 1,25(OH)₂D₃, the most active metabolite of vitamin D₃, is a potent inhibitor of the expression of the hematopoietic growth factor GM-CSF in PHA-activated normal human peripheral blood lymphocytes (PBL). The 1,25(OH)₂D₃ regulated both protein and mRNA accumulation of GM-CSF, and this down-regulation occurred at concentrations close to those in vivo (Fig. 1). The recent reports that activated macrophages synthesize 1,25(OH)₂D₃ (12, 13) further indicate that 1,25(OH)₂D₃ might interact with GM-CSF production at a local level. Our time-response studies indicate that 1,25(OH)₂D₃ can influence GM-CSF expression by PBL in later stages of mitogenesis (Fig. 1 E). The concentrations of 1,25(OH)₂D₃ achieving half-maximal response (ED₅₀) were 5 x 10⁻¹¹ M and 5 x 10⁻¹⁰ M for GM-CSF mRNA levels and GM-CSF protein activity, respectively. These differences in the ED₅₀ can be explained by the greater sensitivity and specificity of the RNA blot technique compared with the clonogenic assay in soft agar. In the clonogenic assay, CM from PHA-stimulated lymphocytes was used which, besides GM-CSF, also contains an admixture of other growth factors, including interleukin 3 and other lymphokines. These additional factors may have decreased both the sensitivity and specificity of the clonogenic assay. Similar to PBL, the 1,25(OH)₂D₃ sensitively inhibited mRNA accumulation of GM-CSF by the HTLV-1 immortalized T lymphocytes (S-LB1) derived from a normal individual (19) (Fig. 2 A).

The 1,25(OH)₂D₃ did not markedly affect mRNA levels for the IL-2 receptor in either the PHA-activated PBL or S-LB1 cells which constitutively produce high levels of IL-2 receptors (Figs. 1 C, 2 C). This suggests that 1,25(OH)₂D₃ does not nonspecifically decrease levels of mRNA in lymphocytes. The 1,25(OH)₂D₃ inhibited total cellular RNA synthesis in S-LB1 cells as determined by incorporation of [³⁴C]uridine into TCA precipitable counts (Table I). This inhibition of total RNA, however, was much less pronounced and less rapid as compared with the decrease in GM-CSF mRNA in the same cells (4 and 52% inhibition, respectively, after exposure for 6 h to 1,25(OH)₂D₃ [Fig. 2 B, Table I]).

Several recent reports suggested that 1,25(OH)₂D₃ may be capable of immunoregulation similar to the glucocorticoids. Tsoukas et al. showed that 1,25(OH)₂D₃ inhibited the lymphocyte growth-promoting factor IL-2 by PBL (10). Studies using different vitamin D₃ metabolites suggested that the effect of 1,25(OH)₂D₃ was probably mediated by a specific receptor. Likewise, Rigby et al. demonstrated that 1,25(OH)₂D₃ was a potent inhibitor of PHA-induced lymphocyte proliferation, achieving a 70% inhibition of [³⁴H]thymidine incorporation after 72 h in culture (9). Another study also showed that 1,25(OH)₂D₃

**Figure 3.** (A) Regulation of GM-CSF mRNA by different vitamin D metabolites in S-LB1 cells (Northern blot). S-LB1 cells were exposed for 48 h to different vitamin D metabolites (10⁻⁴ M). (B) Regulation of GM-CSF mRNA by 1,25(OH)₂D₃ in the HTLV-1-immortalized T lymphocyte line Ab-VDR which was derived from a patient with vitamin D-resistant rickets, type II (Northern blot). S-LB1 cells (S) and Ab-VDR cells (V) were cultured for 48 h in the presence of 1,25(OH)₂D₃ (10⁻⁸ and 10⁻¹⁰ M). (C) Analysis of IL-2 mRNA in S-LB1 cells (Northern blot). Using an IL-2 cDNA probe, a single band could be detected from RNA of PHA-activated PBL at 0.9 kb (Lymph, positive control) consistent with IL-2 mRNA; RNA from HL-60 promyelocytic leukemia cells was used as a negative control. Analysis was performed as described in Fig. 1 and Methods. Each lane in A–C contains 30 µg RNA. A single band at 0.9 kb (A and B) was detected when probed with GM-CSF cDNA.

**Colony-stimulating Factor Regulation by 1,25-Dihydroxyvitamin D₃** 1703
inhibited the proliferation and IL-2 protein production by helper T lymphocytes (8). Similarly, 1,25(OH)₂D₃ decreased the antigen-induced proliferation and IL-2 protein synthesis by cloned Ia-restricted T cell hybridomas after 24 h in culture (11). Taken together, these studies revealed a possible immunoregulatory role for 1,25(OH)₂D₃ that has not previously been appreciated.

The 1,25(OH)₂D₃ receptors are not present in resting T lymphocytes, but do appear 24 h after mitogenic stimulation (4). The HTLV-I-immortalized T-cell lines constitutively express 1,25(OH)₂D₃ receptors. Our experiments using different vitamin D₃ metabolites suggest that the inhibition of the GM-CSF expression by 1,25(OH)₂D₃ is most likely mediated through specific cellular receptors (Fig. 3 A). The potency of these compounds to reduce mRNA levels of GM-CSF paralleled their known affinity to bind to the specific cellular receptor in other tissues (31). Furthermore, our results are in accordance with the reported dissociation constant of 3.8 × 10⁻¹⁰ M for 1,25(OH)₂D₃ by PHA-activated PBL (3). A more direct evidence for this assumption of a receptor-mediated mechanism relies on our study using a HTLV-I-immortalized T lymphocyte line (Ab-VDR) that was derived from a patient with vitamin D-resistant rickets type II. Exposure of Ab-VDR cells to 1,25(OH)₂D₃ resulted in only a small decrease of GM-CSF mRNA levels compared with the marked decrease in S-LB1 cells (Fig. 3 B). These results are consistent with our observation that Ab-VDR cells have undetectable 1,25(OH)₂D₃ receptors, whereas the 1,25(OH)₂D₃-sensitive S-LB1 cells display 13 fmol 1,25(OH)₂D₃ receptors/10⁶ cells, as determined by sucrose density gradient and DNA chromatography analyses (H. P. Koehler and A. W. Norman, unpublished observations). The fact that Ab-VDR cells responded at all to 1,25(OH)₂D₃ suggests that either these cells have a low number of receptors not detectable by the present techniques or very high concentrations of 1,25(OH)₂D₃ can affect all cells independent of expression of 1,25(OH)₂D₃ receptors. Studies are currently under way to analyze the 1,25(OH)₂D₃ receptors in these cells by using a specific cDNA probe for this hormone receptor. Koren et al. recently reported that peripheral blood mononuclear cells from patients with vitamin D-resistant rickets type II do not express 1,25(OH)₂D₃ receptors, even after mitogenic stimulation (32). Moreover, proliferation of these lymphocytes could not be inhibited after a 72-h exposure to 1,25(OH)₂D₃, in contrast to the normal cells.

Because prior studies showed that 1,25(OH)₂D₃ inhibited the production of IL-2 (9, 10, 34), we questioned whether 1,25(OH)₂D₃ might mediate its inhibitory effect on the expression of GM-CSF indirectly through a down-regulation of IL-2 production. Addition of very high concentrations of IL-2 (200 ng/ml) slightly abrogated but did not reverse the inhibition of GM-CSF protein production by 1,25(OH)₂D₃ in PBL (Fig. 1 A). Furthermore, we observed that S-LB1 cells did not express IL-2 mRNA (Fig. 3 C). This T-cell line, therefore, provided an unusual tool to study our assumption of a possible IL-2-independent regulation of GM-CSF expression by 1,25(OH)₂D₃. Our dose-response and time-course experiments clearly showed that 1,25(OH)₂D₃ sensitively inhibited GM-CSF mRNA levels by S-LB1 cells in an IL-2-free system (Fig. 2, A and B). Taken together, our experiments suggest that 1,25(OH)₂D₃ can regulate independently of IL-2 the expression of a lymphokine in transformed T lymphocytes. The effect of 1,25(OH)₂D₃ on normal human PBL seems to be mostly but not totally independent from IL-2.

Our study using [³H]thymidine showed no significant inhibition of the proliferation of PHA-activated lymphocytes by 1,25(OH)₂D₃. Other investigators, however, found a marked inhibition of the lymphocyte proliferation by 1,25(OH)₂D₃, as mentioned above (8, 9, 11). This discrepancy might be explained by the fact that the PBL in the other experiments were cultured for 72 h in the presence of PHA and 1,25(OH)₂D₃, whereas in our study, [³H]thymidine incorporation was determined at 48 h of culture. Our results suggest that the inhibition of GM-CSF production by 1,25(OH)₂D₃ is not necessarily linked to its reported antiproliferative properties.

How does 1,25(OH)₂D₃ regulate the expression of GM-CSF? In the case of glucocorticoids, studies showed that mouse mammary tumor virus DNA contains regions to which the glucocorticoid-receptor complex can specifically bind. Transcription is directly stimulated by interaction of the glucocorticoid-receptor complex with DNA sequences adjacent to the promoter (reviewed in reference 35). In a parallel fashion to the glucocorticoids, the 1,25(OH)₂D₃ receptor complex might specifically bind to certain regions of DNA and inhibit the transcription of the GM-CSF gene either directly or via a transacting mechanism. Vanic et al., however, recently reported that dexamethasone regulated the expression of the alpha-1-acid glycoprotein at the posttranscriptional level (36). Preliminary experiments by us using in vitro nuclear run-on assays suggest that 1,25(OH)₂D₃ affects the stability of GM-CSF mRNA.

In summary, our study shows that 1,25(OH)₂D₃ inhibits the expression of GM-CSF by PBL and a HTLV-I immortalized T lymphocyte line at the mRNA level. This down-regulation is mediated by a specific 1,25(OH)₂D₃ receptor and can further occur independently of IL-2. We conclude that 1,25(OH)₂D₃ might be important as a regulatory hormone in hematopoiesis.

Acknowledgments

We would like to thank Suzanne Bookstaver and Regina Simon for their excellent secretarial help, Dr. S. Clarke for generously providing the IL-2 cDNA, Dr. T. Nikaido for kindly providing the IL-2 receptor cDNA, Dr. J. Besemer for generously providing recombinant IL-2, and Dr. M. Uskokovic for kindly providing the vitamin D metabolites.

This work was supported by United States Public Health Service grants CA-26038, CA-32737, CA-33936, CA-30512, and CA-32428, the Dr. Murray Geisler Memorial Fund, the Louis Fajin Leukemia Research Foundation (Dr. Koehler), AM-14.750-014 (Dr. Koehler and Dr. Norman), the Deutsche Forschungsgemeinschaft (Dr. Reichel), CA-40136 (Dr. Gasson), and the Swiss and Bernese Cancer Ligues (Dr. Tobler).

References


